Articles related to PATIENT ADHERENCE

A network meta-analysis of 716 randomized trials and 159,362 participants found ARB-based regimens had the lowest rates of treatment discontinuation due to adverse effects, with the ARB-CCB combination ranking as the best-tolerated dual-drug option among antihypertensive regimens examined.

A clinical review outlines how OBGYNs can integrate GLP-1 receptor agonist therapy into obesity care for women of reproductive age, with attention to fertility, contraception, and adherence.

Lerochol (lerodalcibep-liga), a once-monthly self-administered PCSK9 inhibitor, is now commercially available as adjunctive LDL-C-lowering therapy for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

The FDA approved a supplemental NDA adding randomized withdrawal trial data to the lumateperone label, supporting its role in long-term maintenance and relapse prevention in adults with schizophrenia.

Switching Parkinson’s patients to Crexont added more than three hours of daily symptom control in interim Phase 4 data. Here’s how to read an open-label, sponsor-run signal.

The OSPREY trial puts proximal hypoglossal nerve stimulation on the map for moderate-to-severe OSA, with strong short-term numbers and the limitations a small unblinded RCT carries.